Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2020 Sep 28

PMID 32983132

Citations 108

Authors

Elizabeth L Siegler

Saad S Kenderian

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor T (CART) cell immunotherapy has been remarkably successful in treating certain relapsed/refractory hematological cancers. However, CART cell therapy is also associated with toxicities which present an obstacle to its wider adoption as a mainstay for cancer treatment. The primary toxicities following CART cell administration are cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). New insights into the mechanisms of these toxicities have spurred novel treatment options. In this review, we summarize the available literature on the clinical manifestations, mechanisms, and treatments of CART-associated CRS and ICANS.

Citing Articles

Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study.

Li D, Liu R, Fu Z, Yang F, Ma L, Guo Y Front Immunol. 2025; 16:1532460.

PMID: 40078989 PMC: 11897563. DOI: 10.3389/fimmu.2025.1532460.

New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.

Luo C, Min X, Zhang D Front Immunol. 2025; 15:1539696.

PMID: 39896817 PMC: 11782189. DOI: 10.3389/fimmu.2024.1539696.

Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology.

Youssef E, Fletcher B, Palmer D Front Med (Lausanne). 2025; 11:1527600.

PMID: 39871848 PMC: 11769984. DOI: 10.3389/fmed.2024.1527600.

Thrombocytopenia in Critically Ill Children: A Review for Practicing Clinicians.

Totapally B, Totapally A, Martinez P Children (Basel). 2025; 12(1).

PMID: 39857914 PMC: 11764412. DOI: 10.3390/children12010083.

CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management.

Norton J, Stiff P Discov Oncol. 2025; 16(1):49.

PMID: 39812904 PMC: 11735762. DOI: 10.1007/s12672-025-01776-0.

References

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Ceschi A, Noseda R, Palin K, Verhamme K . Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Front Pharmacol. 2020; 11:557. PMC: 7212758. DOI: 10.3389/fphar.2020.00557. View

Fitzgerald J, Weiss S, Maude S, Barrett D, Lacey S, Melenhorst J . Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2016; 45(2):e124-e131. PMC: 5452983. DOI: 10.1097/CCM.0000000000002053. View

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

Budde L, Berger C, Lin Y, Wang J, Lin X, Frayo S . Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS One. 2013; 8(12):e82742. PMC: 3866194. DOI: 10.1371/journal.pone.0082742. View

Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X . Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. Front Immunol. 2019; 10:2664. PMC: 6863137. DOI: 10.3389/fimmu.2019.02664. View

10.

Mitsuyasu R, Anton P, Deeks S, Scadden D, Connick E, Downs M . Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood. 2000; 96(3):785-93. View

11.

Yanez L, Sanchez-Escamilla M, Perales M . CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere. 2019; 3(2):e186. PMC: 6746032. DOI: 10.1097/HS9.0000000000000186. View

12.

Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A . Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016; 375(26):2561-9. PMC: 5390684. DOI: 10.1056/NEJMoa1610497. View

13.

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

14.

Gill S, Vides V, Frey N, Hexner E, Metzger S, OBrien M . Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022; 6(21):5774-5785. PMC: 9647791. DOI: 10.1182/bloodadvances.2022007317. View

15.

Wang X, Chang W, Wong C, Colcher D, Sherman M, Ostberg J . A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011; 118(5):1255-63. PMC: 3152493. DOI: 10.1182/blood-2011-02-337360. View

16.

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331. PMC: 5482103. DOI: 10.1182/blood-2017-02-769208. View

17.

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

18.

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

19.

Giavridis T, van der Stegen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M . CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24(6):731-738. PMC: 6410714. DOI: 10.1038/s41591-018-0041-7. View

20.

Klebanoff C, Khong H, Antony P, Palmer D, Restifo N . Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005; 26(2):111-7. PMC: 1388277. DOI: 10.1016/j.it.2004.12.003. View